|
RESEARCH ALERT-Prudential cuts 5 biotechs, upgrades one TUESDAY, MAY 29, 2001 12:00 PM - Reuters NEW YORK, May 29 (Reuters) - Prudential Securities downgraded five development-stage biotech companies and upgraded another after reevaluating its ratings in accord with company-wide rating system changes. The downgraded biotechs include Ista Pharmaceuticals Inc. (NASDAQ NM:ISTA) and ViroLogic Inc. (NASDAQ NM:VLGC), which were dropped to hold from strong buy, citing capital risks. Corvas International Inc. (NASDAQ NM:CVAS) and Texas Biotechnology Corp. (AMEX:TXB) were also lowered to hold from strong buy, due to clinical development remaining in a quiet period. Triangle Pharmaceuticals Inc. (NASDAQ NM:VIRS) also went to a hold, citing valuation and commercial risk. Analyst John Sonnier said the four fundamental risks for these companies are management/infrastructure, technical, regulatory, and capital risk. Sonnier said seven of the firm`s former strong buy-rated stocks were given the firm`s now-highest buy ratings; including Amylin Pharmaceuticals Inc. (NASDAQ NM:AMLN), Cerus Corp. (NASDAQ NM:CERS), Guilford Pharmaceuticals Inc. (NASDAQ NM:GLFD), Insmed Inc. (NASDAQ NM:INSM), Pozen Inc. (NASDAQ NM:POZN), Scios Inc. (NASDAQ NM:SCIO), and Trimeris Inc. (NASDAQ NM:TRMS). Neose Technologies (NASDAQ NM:NTEC) was upgraded to buy from hold. REUTERS Rtr 12:00 05-29-01 Selector Code: reuco Copyright 2001, Reuters News Service Quelle: http://www.bigchart.com |
|
| aus der Diskussion: | GUILFORD PHARMACEUTICALS - PART III |
| Autor (Datum des Eintrages): | Maiestro (31.05.01 01:12:49) |
| Beitrag: | 4 von 66 (ID:3631709) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |